Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full
CompanyDeals

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full

BioArctic AB (OTCMKTS: BRCTF) announced that Novartis AG (NYSE: NVS) has notified the company of its decision to terminate the Option, Collaboration and License Agreement entered into in August 2025.…

Jinhai Medical Signs Strategic Cooperation MOU with Digital Health China – Exploring Business Operations Collaboration and Equity Investment in Medical AI

Jinhai Medical Signs Strategic Cooperation MOU with Digital Health China – Exploring Business Operations Collaboration and Equity Investment in Medical AI

Fresenius Medical Care Inks Decade‑Long Biosimilar Partnership with WuXi Biologics – Rights to Up to 37 Candidates in Industry's Largest Deal of Its Kind

Fresenius Medical Care Inks Decade‑Long Biosimilar Partnership with WuXi Biologics – Rights to Up to 37 Candidates in Industry’s Largest Deal of Its Kind

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

InxMed Presents Positive Data for FAK Inhibitor Ifebemtinib at ESMO 2023

CompanyDrug

CDE Grants Priority Review to Pearl Biotech’s Breatinib for Glioblastoma Treatment

Company

Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand

CompanyDrug

BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC

CompanyDeals

MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates

CompanyDrug

Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial

CompanyDrug

BeiGene’s Tislelizumab Shows Promising Results in ESMO Presentations for GC/GEJC and NSCLC

CompanyDrug

BeiGene Submits Supplementary BLA for Tislelizumab in Small Cell Lung Cancer

Show More